ALX Oncology Shares Soar As FDA Grants Orphan Drug Status To Blood Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ: ALXO) Evorpacept for the treatment of patients with acute myeloid leukemia (AML).
Benzinga ·